Twitter accounts hyped US firm seeking trials for India-made Covid vaccine

Ocugen sought FDA approval for Covaxin in October, then a seeming coordinated social media effort lifted its stock.

A network of Twitter accounts pushed messages to boost the share price of a biotech company as it sought approval to run a clinical trial of its Covid-19 vaccine, according to research provided to Bloomberg News. 

The tweets promoted stock for Ocugen Inc., which is based in Malvern, Pennsylvania, at rates well above market value, according to research by Alethea Group, a startup that tracks disinformation. The company’s share price nearly doubled in a little more than a week.

The findings suggest a coordinated social media effort to sway interest in an otherwise little known medical technology company, according to